AUTHOR=Atalar Arife Çimen , Özge Aynur , Türk Bengi Gül , Ekizoğlu Esme , Kurt Gök Duygu , Baykan Betül , Ayta Semih , Erdoğan Füsun Ferda , Yeni Seher Naz , Taşdelen Bahar , IDEM Study Group , Velioğlu Sibel K. , Yapıcı Zuhal , Midi İpek , Serap Saygı , Ulufer Çelebi , Sarıca Darol Elif , Ağan Kadriye , Ayç Senem , Gazioğlu Sibel , Vildan Okudan Zeynep , Görkem Şirin Nermin , Bebek Nerses , Dericioğlu Neşe , Güçlü Altun İlknur , Destina Yalçın Ayşe , Sürmeli Reyhan , Osman Erdinç Oğuz , Erdal Abidin , İlhan Algın Demet , Kutlu Gülnihal , Bek Semai , Erdal Yüksel , Övünç Özön Akçay , Reyhani Aylin , Güldiken Babürhan , Baklan Barış , Oğuz Genç Bülent , Aykutlu Altindağ Ebru , Karahan Gökçen , Koç Güray , Mısırlı Handan , Öztura İbrahim , Aslan-Kara Kezban , Merve Melodi Çakar , Türkmen Nur , Bulut Onur , Ömer Karadaş , Kesim Çahin Özlem , Ferik Sevgi , Mehmet Taylan Peköz , Topaloğlu Pınar , Üstün Özek Sibel , Düzgün Ülkühan , Yayla Vildan , Gömceli Yasemin , Ünlüsoy Acar Zeynep TITLE=Diagnosis of comorbid migraine without aura in patients with idiopathic/genetic epilepsy based on the gray zone approach to the International Classification of Headache Disorders 3 criteria JOURNAL=Frontiers in Neurology VOLUME=13 YEAR=2023 URL=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2022.1103541 DOI=10.3389/fneur.2022.1103541 ISSN=1664-2295 ABSTRACT=Background

Migraine without aura (MwoA) is a very frequent and remarkable comorbidity in patients with idiopathic/genetic epilepsy (I/GE). Frequently in clinical practice, diagnosis of MwoA may be challenging despite the guidance of current diagnostic criteria of the International Classification of Headache Disorders 3 (ICHD-3). In this study, we aimed to disclose the diagnostic gaps in the diagnosis of comorbid MwoA, using a zone concept, in patients with I/GEs with headaches who were diagnosed by an experienced headache expert.

Methods

In this multicenter study including 809 consecutive patients with a diagnosis of I/GE with or without headache, 163 patients who were diagnosed by an experienced headache expert as having a comorbid MwoA were reevaluated. Eligible patients were divided into three subgroups, namely, full diagnosis, zone I, and zone II according to their status of fulfilling the ICHD-3 criteria. A Classification and Regression Tree (CART) analysis was performed to bring out the meaningful predictors when evaluating patients with I/GEs for MwoA comorbidity, using the variables that were significant in the univariate analysis.

Results

Longer headache duration (<4 h) followed by throbbing pain, higher visual analog scale (VAS) scores, increase of pain by physical activity, nausea/vomiting, and photophobia and/or phonophobia are the main distinguishing clinical characteristics of comorbid MwoA in patients with I/GE, for being classified in the full diagnosis group. Despite being not a part of the main ICHD-3 criteria, the presence of associated symptoms mainly osmophobia and also vertigo/dizziness had the distinguishing capability of being classified into zone subgroups. The most common epilepsy syndromes fulfilling full diagnosis criteria (n = 62) in the CART analysis were 48.39% Juvenile myoclonic epilepsy followed by 25.81% epilepsy with generalized tonic-clonic seizures alone.

Conclusion

Longer headache duration, throbbing pain, increase of pain by physical activity, photophobia and/or phonophobia, presence of vertigo/dizziness, osmophobia, and higher VAS scores are the main supportive associated factors when applying the ICHD-3 criteria for the comorbid MwoA diagnosis in patients with I/GEs. Evaluating these characteristics could be helpful to close the diagnostic gaps in everyday clinical practice and fasten the diagnostic process of comorbid MwoA in patients with I/GEs.